| Makale Türü |
|
||
| Dergi Adı | BIOMEDICINE & PHARMACOTHERAPY | ||
| Dergi ISSN | 0753-3322 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 07-2014 |
| Kabul Tarihi | 12-04-2026 | Yayınlanma Tarihi | – |
| Cilt / Sayı / Sayfa | 68 / 6 / 737–743 | DOI | 10.1016/j.biopha.2014.07.003 |
| Makale Linki | http://linkinghub.elsevier.com/retrieve/pii/S0753332214000730 | ||
| Özet |
| Gemcitabine is an anticancer drug used in the treatment of different cancer types, including pancreatic ductal adenocarcinoma. The maximum tolerated dose in humans is restricted by its side effects on healty cells. Furthermore, the fibrotic stroma produced by the pancreatic stellate cells prevents effective delivery of chemotherapeutic agents providing a safe-haven for the cancer cells. This becomes more of a problem considering the short half-life of this drug. Magnetic nanoparticle-based targeted drug delivery systems are a promising alternative to overcome the limitations of classical chemotherapies. The aim of this study is to obtain an effective targeted delivery system for gemcitabine using magnetic nanoparticles (MNPs) and all-trans retinoic acid (ATRA). This dual approach targets the tumor cells and its infrastructure – stellate cells – simultaneously. Gemcitabine and ATRA were loaded onto the PAMAM … |
| Anahtar Kelimeler |
| Gemcitabine | Retinoic acid | PAMAM dendrimer | Nanoparticle | Pancreatic cancer | Stellate cell lines |
| Atıf Sayıları | |
| Google Scholar | 70 |
| Web of Science | 41 |
| Dergi Adı | BIOMEDICINE & PHARMACOTHERAPY |
| Yayıncı | Elsevier Masson s.r.l. |
| Açık Erişim | Evet |
| ISSN | 0753-3322 |
| E-ISSN | 1950-6007 |
| CiteScore | 12,8 |
| SJR | 1,775 |
| SNIP | 1,561 |